Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of 6MW3511 in advanced solid tumors
CTR20222206Phase 2Terminated
- Sponsor
- Maiwei Biotech
- Start
- Sep 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of 6MW3511 in Nonhematologic neoplasms, sponsored by Maiwei Biotech. Started Sep 2022; status: terminated.
02
Drugs
6MW3511
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20222206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222206.